PYC.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 03:09):

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia...

Stats
Šios dienos apimtis	495 259
Vidutinė apimtis	1.82M
Rinkos kapitalizacija	499.27M
EPS	$0 ( 2024-02-25 )
Kita pelno data	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.70
ATR14	$0.00100 (0.93%)

Tūris Koreliacija

Ilgas: 0.06 (neutral)

Trumpas: 0.06 (neutral)

Signal:(55.295) Neutral

PYC Therapeutics Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

PYC Therapeutics Ltd Koreliacija - Valiuta/Žaliavos

0.51
( weak )

0.57
( weak )

0.00
( neutral )

-0.60
( weak negative )

PYC Therapeutics Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$15.81M
Bruto pelnas:	$14.92M (94.42 %)
EPS:	$-0.00700

FY	2023
Pajamos:	$15.81M
Bruto pelnas:	$14.92M (94.42 %)
EPS:	$-0.00700

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2022
Pajamos:	$16.04M
Bruto pelnas:	$15.20M (94.77 %)
EPS:	$-0.00430

Financial Reports:

No articles found.

PYC Therapeutics Ltd

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.